<p>Orchestra BioMed Holdings, Inc.（纳斯达克代码：OBIO - 获取免费报告）的股票被七家覆盖该公司的研究机构一致评定为 “适度买入”，Marketbeat 报道称。一位研究分析师给予该股票卖出评级，一位给予持有评级，四位给予买入评级，还有一位给予强烈买入评级。在过去一年中，更新该股票覆盖的券商的平均一年目标价为 13.80 美元。</p>
<p>获取 <strong>Orchestra BioMed</strong> 的提醒：</p>
<p>OBIO 已成为几份分析师报告的主题。Chardan Capital 在 11 月 13 日的研究报告中重申了 “买入” 评级，并对 Orchestra BioMed 的股票设定了 20.00 美元的目标价。TD Cowen 在 12 月 10 日的报告中开始覆盖 Orchestra BioMed 的股票，并给予该公司 “买入” 评级。最后，巴克莱在 1 月 9 日的报告中将 Orchestra BioMed 的目标价从 11.00 美元上调至 12.00 美元，并给予该股票 “超配” 评级。</p>
<p><strong>查看我们关于 OBIO 的最新研究报告</strong></p>
<h2>Orchestra BioMed 股票表现</h2>
<p>纳斯达克：OBIO 周五开盘价为 3.92 美元。该公司的 50 日简单移动平均为 4.16 美元，200 日简单移动平均为 3.66 美元。Orchestra BioMed 的一年最低价为 2.20 美元，一年最高价为 5.42 美元。该公司的市值为 2.2134 亿美元，市盈率为-2.15，贝塔值为 0.61。该公司的债务与股本比率为 0.32，流动比率为 4.73，速动比率为 4.72。</p>
<h2>机构投资者对 Orchestra BioMed 的看法</h2>
<p>对冲基金和其他机构投资者最近增加或减少了对该股票的持股。Alyeska Investment Group L.P. 在第三季度购买了价值 338.6 万美元的 Orchestra BioMed 新股份。Pathstone Holdings LLC 在第三季度获得了 Orchestra BioMed 的新头寸，价值 249.5 万美元。Vanguard Group Inc. 在第三季度将其在 Orchestra BioMed 的持股增加了 28.0%。Vanguard Group Inc. 目前拥有 1481875 股该公司的股票，价值 367.5 万美元，此前在上个季度购买了 324558 股。683 Capital Management LLC 在第四季度购买了价值约 84.7 万美元的 Orchestra BioMed 新股份。最后，Marshall Wace LLP 在第四季度购买了价值 71.2 万美元的 Orchestra BioMed 新股份。机构投资者和对冲基金持有该公司 53.20% 的股票。</p>
<h2>Orchestra BioMed 公司简介</h2>
<p>（获取免费报告）</p>
<p>Orchestra BioMed, Inc. 纳斯达克：OBIO 是一家临床阶段的生物制药公司，致力于开发针对炎症、纤维化和肿瘤疾病的靶向疗法。该公司的研究专注于新型小分子项目，旨在通过利用专有的前药和靶向抑制剂平台来解决高未满足需求的疾病。Orchestra BioMed 的产品线包括主要候选药物 OBI-3424，这是一种由 AKR1C3 激活的前药，用于治疗特定的实体肿瘤，以及旨在抑制病理性炎症和纤维化的下一代调节剂。</p>
<p>Orchestra BioMed 在北美进行早期和中期临床研究，与关键意见领袖和学术中心紧密合作，以推进其项目。</p>
<h2>另请参阅</h2>
<ul>
<li>我们更看好的五只股票，而不是 Orchestra BioMed</li>
<li>~1.5 万亿美元的 SpaceX IPO：首次公开募股机会</li>
<li>美国的 1776 再次发生</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>家族信托如何帮助保护您的财富</li>
<li>这让我感到愤怒</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0JJTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0JJTw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1000 美元在 Orchestra BioMed 吗？</h2>
<p>在您考虑 Orchestra BioMed 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Orchestra BioMed 并不在名单上。</p>
<p>虽然 Orchestra BioMed 目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

OBIO

纳斯达克生物科技指数 ETF - iShares Nasdaq

纽交所高增长板生物技术指数 ETF - First Trust

2 倍做多纳斯达克生物技术 ETF - ProShares

生物科技 ETF - VanEck Vectors

标普生物技术 3 倍做空 - Direxion

医药突破 ETF - ALPS

动态生物技术与基因组 ETF - Invesco

标普生物技术 ETF - SPDR

<p>Orchestra BioMed Holdings, Inc.（纳斯达克代码：OBIO）获得了七家研究公司的 “适度买入” 共识评级。评级包括一项卖出、一项持有、四项买入和一项强力买入。平均目标价为 13.80 美元，Chardan Capital 设定的目标价为 20.00 美元。该股票开盘价为 3.92 美元，市值为 2.2134 亿美元。机构投资者持有该公司 53.20% 的股份，该公司专注于开发针对炎症和肿瘤疾病的疗法</p>

<p>Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) have been assigned a consensus recommendation of &#34;Moderate Buy&#34; from the seven research firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $13.80.</p>
<div class="lb-trans"><p>Orchestra BioMed Holdings, Inc.（纳斯达克代码：OBIO - 获取免费报告）的股票被七家覆盖该公司的研究机构一致评定为 “适度买入”，Marketbeat 报道称。一位研究分析师给予该股票卖出评级，一位给予持有评级，四位给予买入评级，还有一位给予强烈买入评级。在过去一年中，更新该股票覆盖的券商的平均一年目标价为 13.80 美元。</p>
</div><p>Get <strong>Orchestra BioMed</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Orchestra BioMed</strong> 的提醒：</p>
</div><p>OBIO has been the subject of several analyst reports. Chardan Capital reaffirmed a &#34;buy&#34; rating and issued a $20.00 price objective on shares of Orchestra BioMed in a research note on Thursday, November 13th. TD Cowen initiated coverage on shares of Orchestra BioMed in a report on Wednesday, December 10th. They issued a &#34;buy&#34; rating for the company. Finally, Barclays lifted their price objective on Orchestra BioMed from $11.00 to $12.00 and gave the stock an &#34;overweight&#34; rating in a report on Friday, January 9th.</p>
<div class="lb-trans"><p>OBIO 已成为几份分析师报告的主题。Chardan Capital 在 11 月 13 日的研究报告中重申了 “买入” 评级，并对 Orchestra BioMed 的股票设定了 20.00 美元的目标价。TD Cowen 在 12 月 10 日的报告中开始覆盖 Orchestra BioMed 的股票，并给予该公司 “买入” 评级。最后，巴克莱在 1 月 9 日的报告中将 Orchestra BioMed 的目标价从 11.00 美元上调至 12.00 美元，并给予该股票 “超配” 评级。</p>
</div><p><strong>Check Out Our Latest Research Report on OBIO</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 OBIO 的最新研究报告</strong></p>
</div><h2>Orchestra BioMed Stock Performance</h2>
<div class="lb-trans"><h2>Orchestra BioMed 股票表现</h2>
</div><p>NASDAQ:OBIO opened at $3.92 on Friday. The firm has a 50 day simple moving average of $4.16 and a 200-day simple moving average of $3.66. Orchestra BioMed has a 1-year low of $2.20 and a 1-year high of $5.42. The firm has a market cap of $221.34 million, a PE ratio of -2.15 and a beta of 0.61. The company has a debt-to-equity ratio of 0.32, a current ratio of 4.73 and a quick ratio of 4.72.</p>
<div class="lb-trans"><p>纳斯达克：OBIO 周五开盘价为 3.92 美元。该公司的 50 日简单移动平均为 4.16 美元，200 日简单移动平均为 3.66 美元。Orchestra BioMed 的一年最低价为 2.20 美元，一年最高价为 5.42 美元。该公司的市值为 2.2134 亿美元，市盈率为-2.15，贝塔值为 0.61。该公司的债务与股本比率为 0.32，流动比率为 4.73，速动比率为 4.72。</p>
</div><h2>Institutional Investors Weigh In On Orchestra BioMed</h2>
<div class="lb-trans"><h2>机构投资者对 Orchestra BioMed 的看法</h2>
</div><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Alyeska Investment Group L.P. bought a new stake in shares of Orchestra BioMed during the 3rd quarter valued at $3,386,000. Pathstone Holdings LLC acquired a new position in Orchestra BioMed during the third quarter worth $2,495,000. Vanguard Group Inc. increased its position in shares of Orchestra BioMed by 28.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,481,875 shares of the company's stock worth $3,675,000 after purchasing an additional 324,558 shares during the last quarter. 683 Capital Management LLC bought a new stake in shares of Orchestra BioMed in the 4th quarter valued at about $847,000. Finally, Marshall Wace LLP bought a new stake in Orchestra BioMed in the 4th quarter valued at $712,000. Institutional investors and hedge funds own 53.20% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近增加或减少了对该股票的持股。Alyeska Investment Group L.P. 在第三季度购买了价值 338.6 万美元的 Orchestra BioMed 新股份。Pathstone Holdings LLC 在第三季度获得了 Orchestra BioMed 的新头寸，价值 249.5 万美元。Vanguard Group Inc. 在第三季度将其在 Orchestra BioMed 的持股增加了 28.0%。Vanguard Group Inc. 目前拥有 1481875 股该公司的股票，价值 367.5 万美元，此前在上个季度购买了 324558 股。683 Capital Management LLC 在第四季度购买了价值约 84.7 万美元的 Orchestra BioMed 新股份。最后，Marshall Wace LLP 在第四季度购买了价值 71.2 万美元的 Orchestra BioMed 新股份。机构投资者和对冲基金持有该公司 53.20% 的股票。</p>
</div><h2>Orchestra BioMed Company Profile</h2>
<div class="lb-trans"><h2>Orchestra BioMed 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Orchestra BioMed, Inc NASDAQ: OBIO is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company's research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed's pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.</p>
<div class="lb-trans"><p>Orchestra BioMed, Inc. 纳斯达克：OBIO 是一家临床阶段的生物制药公司，致力于开发针对炎症、纤维化和肿瘤疾病的靶向疗法。该公司的研究专注于新型小分子项目，旨在通过利用专有的前药和靶向抑制剂平台来解决高未满足需求的疾病。Orchestra BioMed 的产品线包括主要候选药物 OBI-3424，这是一种由 AKR1C3 激活的前药，用于治疗特定的实体肿瘤，以及旨在抑制病理性炎症和纤维化的下一代调节剂。</p>
</div><p>Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.</p>
<div class="lb-trans"><p>Orchestra BioMed 在北美进行早期和中期临床研究，与关键意见领袖和学术中心紧密合作，以推进其项目。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than Orchestra BioMed</li>
<li>~$1.5T SpaceX IPO: Pre-IPO Opportunity</li>
<li>America’s 1776 happening again</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>This makes me furious</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Orchestra BioMed</li>
<li>~1.5 万亿美元的 SpaceX IPO：首次公开募股机会</li>
<li>美国的 1776 再次发生</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>家族信托如何帮助保护您的财富</li>
<li>这让我感到愤怒</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0JJTw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=OBIO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Orchestra BioMed Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1000 美元在 Orchestra BioMed 吗？</h2>
</div><p>Before you consider Orchestra BioMed, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Orchestra BioMed 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orchestra BioMed wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Orchestra BioMed 并不在名单上。</p>
</div><p>While Orchestra BioMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Orchestra BioMed 目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Consensus Rating of "Moderate Buy" by Brokerages

Market Beat

Orchestra BioMed

Orchestra BioMed Holdings, Inc.（NASDAQ:OBIO）被券商一致评为 “适度买入”